|
|
|
|
|
Received: 20 January 2021
|
|
|
|
|
|
| [1] |
Aier I, Semwal R, Sharma A, et al. A systematic assessment of statistics, risk factors, and underlying features involved in pancreatic cancer[J]. Cancer Epidemiol, 2019, 58: 104-110.
|
| [2] |
Pachmann K, Clement J H, Schneider C P, et al. Standardized quantification of circulating peripheral tumor cells from lung and breast cancer[J]. Clin Chem Lab Med, 2005, 43(6): 617-627.
|
| [3] |
陈 颐,王小林. 循环肿瘤细胞研究进展及其在PC诊疗中的应用[J]. 复旦学报(医学版), 2018, 45(1):119-136.
|
| [4] |
Ma Y C, Wang L, Yu F L. Recent advances and prospects in the isolation by size of epithelial tumor cells (ISET) methodology[J]. Technol Cancer Res Treat, 2013, 12(4): 295-309.
|
| [5] |
丁善航,修典荣. 胰腺癌循环肿瘤细胞的富集、鉴定方法及预后的评估价值[J]. 中国微创外科杂志, 2019, 19(7):617-621.
|
| [6] |
Yeo T, Tan S J, Lim C L, et al. Microfluidic enrichment for the single cell analysis of circulating tumor cells[J]. Sci Rep, 2016, 6: 22076.
|
| [7] |
Chen K, Amontree J, Varillas J, et al. Incorporation of lateral microfiltration with immunoaffinity for enhancing the capture efficiency of rare cells[J]. Sci Rep, 2020, 10(1): 14210.
|
| [8] |
Su Y, Tian Q, Pan D, et al. Antibody functional microsphere Integrated filter chip with inertial microflow for size-immune-capturing and digital detection of circulating tumor cells[J]. ACS Appl Mater Interfaces, 2019, 11(33): 29569-29578.
|
| [9] |
李兆申,王洛伟. 胰腺癌早期诊断[J]. 武警医学, 2004, 15(1):7-10.
|
| [10] |
李兆申. 胰腺癌早期诊断研究的现状与展望[J]. 解放军医学, 2009, 34(1):7-9.
|
| [11] |
刘艳辉,唐甜甜,孙丽丽. 肿瘤外周血循环细胞对胰腺癌的诊断价值[J]. 解放军医学院学报, 2013, 34(10):1045-1047.
|
| [12] |
吴 斌,陈敏捷,陈 飞,等. 循环肿瘤细胞对胰腺癌诊断价值的Meta分析[J]. 中国普通外科杂志, 2017, 26(3):271-280.
|
| [13] |
Martini V, Timme B S, Fichtner F S, et al. Circulating tumor cells in pancreatic cancer: current perspectives[J]. Cancers (Basel), 2019, 11(11):1659.
|
| [14] |
Hugenschmidt H, Labori K J, Brunborg C, et al. Circulating tumor cells are an independent predictor of shorter survival in patients undergoing resection for pancreatic and periampullary adenocarcinoma[J]. Ann Surg, 2020, 271(3): 549-558.
|
| [15] |
Hugenschmidt H, Labori K J, Borgen E, et al. Preoperative CTC-detection by cellsearch((r)) is associated with early distant metastasis and impaired survival in resected pancreatic cancer[J]. Cancers (Basel), 2021, 13(3):485.
|
| [16] |
Yin L, Pu N, Thompson E, et al. Improved assessment of response status in patients with pancreatic cancer treated with neoadjuvant therapy using somatic mutations and liquid biopsy analysis[J]. Clin Cancer Res, 2021, 27(3): 740-748.
|
| [17] |
Wang Y, Yu X, Hartmann D,et al. Circulating tumor cells in peripheral blood of pancreatic cancer patients and their prognostic role: a systematic review and meta-analysis[J]. HPB (Oxford), 2020, 22(5): 660-669.
|
| [18] |
Mandair D, Khan M S, Lopes A, et al. Prognostic threshold for circulating tumour cells in patients with pancreatic and midgut neuroendocrine tumours[J]. J Clin Endocrinol Metab, 2020,106(3):872-882.
|
| [19] |
Chapman C G, Ayoub F, Swei E,et al. Endoscopic ultrasound acquired portal venous circulating tumor cells predict progression free survival and overall survival in patients with pancreaticobiliary cancers[J]. Pancreatology, 2020, 20(8): 1747-1754.
|
| [20] |
Amantini C, Morelli M B, Nabissi M, et al. Expression profiling of circulating tumor cells in pancreatic ductal adenocarcinoma patients: biomarkers predicting overall survival[J]. Front Oncol, 2019, 9: 874.
|
| [21] |
Poruk K E, Blackford A L, Weiss M J, et al. Circulating tumor cells expressing markers of tumor initiating cells predict poor survival and cancer recurrence in patients with pancreatic ductal adenocarcinoma[J]. Clin Cancer Res, 2017, 23(11): 2681-2690.
|
| [22] |
Labib M, Wang Z, Ahmed S U, et al. Tracking the expression of therapeutic protein targets in rare cells by antibody mediated nanoparticle labelling and magnetic sorting[J]. Nat Biomed Eng, 2021, 5(1): 41-52.
|
| [23] |
Sheng W, Ogunwobi O O, Chen T, et al. Capture, release and culture of circulating tumor cells from pancreatic cancer patients using an enhanced mixing chip[J]. Lab Chip, 2014, 14(1): 89-98.
|
| [24] |
Rivera-Baez L, Lohse I, Lin E, et al. Expansion of circulating tumor cells from patients with locally advanced pancreatic cancer enable patient derived xenografts and functional studies for personalized medicine[J]. Cancers (Basel), 2020, 12(4):1011.
|
| [25] |
Nagarkar R, Patil D, Limaye S, et al. Liquid biopsy and multi-analyte testing guided treatment of HER2 positive periampullary adenocarcinoma with durable complete response after trastuzumab based therapy[J]. Oncotarget, 2020, 11(45): 4195-4200.
|
| [26] |
Wang D, Ge C, Liang W, et al. In Vivo enrichment and elimination of circulating tumor cells by using a black phosphorus and antibody functionalized intravenous catheter[J]. Adv Sci (Weinh), 2020, 7(17): 2000940.
|
| [27] |
Franses J W, Philipp J, Missios P, et al. Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target[J]. Nat Commun, 2020, 11(1): 3303.
|
| [28] |
Fernandez-Lazaro D, Hernandez J L G, Garcia A C, et al. Clinical perspective and translational oncology of liquid biopsy[J]. Diagnostics (Basel), 2020, 10(7):443.
|
| [29] |
Hasanain A, Blanco B A, Yu J, et al. The importance of circulating and disseminated tumor cells in pancreatic cancer[J]. Surg Open Sci, 2019, 1(2): 49-55.
|
| [30] |
庄云英,张海燕,曾清芳. CRISPR/Cas9技术及其在胰腺癌研究中的应用进展[J]. 武警医学, 2020, 31(7):631-636.
|
|
|
2021, Vol. 32 
